[Prevalence and treatment of hypercholesterolemia in patients with manifest vascular disease according to practice guidelines of the current cholesterol consensus]

Ned Tijdschr Geneeskd. 2000 Apr 8;144(15):706-9.
[Article in Dutch]

Abstract

Objective: To determine the prevalence of hypercholesterolaemia and the use of lipid-lowering medication in patients with a manifest vascular disease.

Design: Prospective, cross-sectional.

Methods: In patients who visited the University Medical Centre Utrecht, the Netherlands, for the first time with a manifestation of atherosclerosis in the period 1 September 1996-15 November 1998, we determined by a single measurement of the cholesterol if they were eligible for lipid-lowering medication according to the cholesterol cut-off value mentioned in the new Dutch cholesterol guidelines (1998) of the Dutch Institute for Health Care Improvement.

Results: The study group comprised 737 patients: 539 (73%) males and 198 (27%) females, with a mean age of 62 year. 500 (68%) were eligible for lipid-lowering treatment. 66 patients (9%) were being treated according to the guidelines and in 106 (14%) the aim of a cholesterol lower than 5.0 mmol/1 was not reached despite cholesterol lowering medication. In 328 patients (45%) hyperlipidaemia was not treated pharmacologically.

Conclusion: Two-thirds of the patients with manifest vascular disease had hypercholesterolaemia. Many of these patients were not yet being treated.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Anticholesteremic Agents / therapeutic use*
  • Arteriosclerosis / etiology*
  • Cross-Sectional Studies
  • Drug Utilization / statistics & numerical data
  • Female
  • Guideline Adherence* / statistics & numerical data
  • Humans
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / epidemiology
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Population Surveillance
  • Practice Guidelines as Topic
  • Prevalence
  • Prospective Studies

Substances

  • Anticholesteremic Agents